These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12879681)

  • 1. Immunoglobulin therapy in non-menstrual streptococcal toxic shock syndrome.
    Murthy BV; Nelson RA; Mannion PT
    Anaesth Intensive Care; 2003 Jun; 31(3):320-3. PubMed ID: 12879681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of polyspecific intravenous immunoglobulin therapy in streptococcal toxic shock syndrome.
    Arends JE; Harkisoen S
    Clin Infect Dis; 2015 Jan; 60(2):324. PubMed ID: 25313253
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous immunoglobulin therapy for toxic shock syndrome.
    Barry W; Hudgins L; Donta ST; Pesanti EL
    JAMA; 1992 Jun; 267(24):3315-6. PubMed ID: 1597914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review.
    Perez CM; Kubak BM; Cryer HG; Salehmugodam S; Vespa P; Farmer D
    Am J Med; 1997 Jan; 102(1):111-3. PubMed ID: 9209207
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics.
    Chiu CH; Ou JT; Chang KS; Lin TY
    Infection; 1997; 25(1):47-8. PubMed ID: 9039540
    [No Abstract]   [Full Text] [Related]  

  • 6. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome.
    Stevens DL
    Clin Infect Dis; 1998 Mar; 26(3):639-41. PubMed ID: 9524836
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.
    Linnér A; Darenberg J; Sjölin J; Henriques-Normark B; Norrby-Teglund A
    Clin Infect Dis; 2014 Sep; 59(6):851-7. PubMed ID: 24928291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptococcal Toxic Shock Syndrome Caused by Group G Streptococcus, United Kingdom.
    Baxter M; Morgan M
    Emerg Infect Dis; 2017 Jan; 23(1):127-129. PubMed ID: 27983491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
    Darenberg J; Söderquist B; Normark BH; Norrby-Teglund A
    Clin Infect Dis; 2004 Mar; 38(6):836-42. PubMed ID: 14999628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravenous immunoglobulin therapy in non-menstrual staphylococcal toxic shock syndrome].
    Hureau M; Saint-Léger P
    Med Mal Infect; 2018 Feb; 48(1):70-72. PubMed ID: 29050863
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult quest.
    Valiquette L; Low DE; McGeer AJ
    Clin Infect Dis; 2009 Nov; 49(9):1377-9. PubMed ID: 19788361
    [No Abstract]   [Full Text] [Related]  

  • 12. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome.
    Schrage B; Duan G; Yang LP; Fraser JD; Proft T
    Clin Infect Dis; 2006 Sep; 43(6):743-6. PubMed ID: 16912949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.
    Kaul R; McGeer A; Norrby-Teglund A; Kotb M; Schwartz B; O'Rourke K; Talbot J; Low DE
    Clin Infect Dis; 1999 Apr; 28(4):800-7. PubMed ID: 10825042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Superantigens and toxic shock syndrome. A report of three cases treated with intravenous gammaglobulin].
    Vázquez García RE; Hernández Bautista V; Espinosa Padilla S
    Rev Alerg Mex; 2006; 53(5):183-8. PubMed ID: 17357565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survey of physician's attitudes regarding management of severe group A streptococcal infections.
    Valiquette L; Low DE; Chow R; McGeer AJ
    Scand J Infect Dis; 2006; 38(11-12):977-82. PubMed ID: 17148064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of immunoglobulins in the treatment of patients with sepsis and septic shock.
    Bojić I; Begović V; Trnjak Z; Dokić M
    Vojnosanit Pregl; 1998; 55(2 Suppl):75-8. PubMed ID: 9623363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High-dose immunoglobulin--life-saving in invasive group A streptococcal infection. Report of eleven cases with only one fatality].
    Arnholm B; Lundqvist A; Strömberg A
    Lakartidningen; 2004 Aug; 101(35):2642-4. PubMed ID: 15458217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome.
    Abinun M; Cant AJ
    Lancet; 1994 Jan; 343(8892):300. PubMed ID: 7905129
    [No Abstract]   [Full Text] [Related]  

  • 19. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial.
    Hentrich M; Fehnle K; Ostermann H; Kienast J; Cornely O; Salat C; Ubelacker R; Buchheidt D; Behre G; Hiddemann W; Schiel X
    Crit Care Med; 2006 May; 34(5):1319-25. PubMed ID: 16540956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
    Darenberg J; Ihendyane N; Sjölin J; Aufwerber E; Haidl S; Follin P; Andersson J; Norrby-Teglund A;
    Clin Infect Dis; 2003 Aug; 37(3):333-40. PubMed ID: 12884156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.